Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Fedorov, US
Gennadi Fedorov, Blairstown, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090266915 | Spraying device apparatus - A spraying device includes a housing that has a spraying unit and a trigger assembly. The spraying unit is a removable insert within the housing. The spraying unit includes an air chamber that is coupled to a liquid tank. A front end portion of the air chamber has a nozzle. The air chamber receives a liquid tube that opens in the nozzle. The liquid tube receives a needle and the needle and the liquid tube are coaxial with each other. The trigger assembly controls the flow of liquid through the liquid tube by positioning a tapered front end of the needle. The trigger assembly includes a trigger that has a first position and a second position. In the first position, the opening of the liquid tube is closed by the needle. In a second position, the liquid tube is opened to discharge a liquid from an opening of the liquid tube. | 10-29-2009 |
| 20090266916 | Spraying device apparatus - A spraying device includes a housing that has a spraying unit and a trigger assembly. The spraying unit is a removable insert within the housing. The spraying unit includes an air chamber that is coupled to a liquid tank. A front end portion of the air chamber has a nozzle. The air chamber receives a liquid tube that opens in the nozzle. The liquid tube receives a needle and the needle and the liquid tube are coaxial with each other. The trigger assembly controls the flow of liquid through the liquid tube by positioning a tapered front end of the needle. The trigger assembly includes a trigger that has a first position and a second position. In the first position, the opening of the liquid tube is closed by the needle. In a second position, the liquid tube is opened to discharge a liquid from an opening of the liquid tube. | 10-29-2009 |
| 20100147883 | Spraying device apparatus - A spraying device includes a housing that has a spraying unit and a trigger assembly. The spraying unit is a removable insert within the housing. The spraying unit includes an air chamber that is coupled to a liquid tank. A front end portion of the air chamber has a nozzle. The air chamber receives a liquid tube that opens in the nozzle. The liquid tube receives a needle and the needle and the liquid tube are coaxial with each other. The trigger assembly controls the flow of liquid through the liquid tube by positioning a tapered front end of the needle. The trigger assembly includes a trigger that has a first position and a second position. In the first position, the opening of the liquid tube is closed by the needle. In a second position, the liquid tube is opened to discharge a liquid from an opening of the liquid tube. | 06-17-2010 |
| 20100170964 | Spraying device apparatus - A spraying device includes a housing that has a spraying unit and a trigger assembly. The spraying unit is a removable insert within the housing. The spraying unit includes an air chamber that is coupled to a liquid tank. A front end portion of the air chamber has a nozzle. The air chamber receives a liquid tube that opens in the nozzle. The liquid tube receives a needle and the needle and the liquid tube are coaxial with each other. The trigger assembly controls the flow of liquid through the liquid tube by positioning a tapered front end of the needle. The trigger assembly includes a trigger that has a first position and a second position. In the first position, the opening of the liquid tube is closed by the needle. In a second position, the liquid tube is opened to discharge a liquid from an opening of the liquid tube. | 07-08-2010 |
Nikolai Fedorov, Winston-Salem, NC US
| Patent application number | Description | Published |
|---|---|---|
| 20090048290 | 2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL-BENZYOFURAN-- 2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF - The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems. | 02-19-2009 |
Vadim V. Fedorov, St. Louis, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20090204164 | METHOD AND DEVICE FOR LOW-ENERGY TERMINATION OF ATRIAL TACHYARRHYTHMIAS - Methods for treating atrial arrhythmias can involve configuring an implantable arrhythmia treatment device. A device can be configured after implantation when the patient is fully conscious and after any pain suppression medication has worn off. The device is caused to apply a phased unpinning far field therapy to the patient in response to detection of an arrhythmia via a far field configuration of electrodes. An indication of a pain sensation of the patient and the effectiveness of the treatment in response to the therapy can then be received. In response, at least one of a set of therapy parameters is adjusted and the steps are repeated until it is determined that an effective treatment is provide at a pain sensation that is tolerable to the patient. The device is then programmed to automatically treat arrhythmias detected in the patient with the determined set of therapy parameters. | 08-13-2009 |
| 20110009916 | METHOD AND DEVICE FOR THREE-STAGE ATRIAL CARDIOVERSION THERAPY - Methods and apparatus for a three-stage atrial cardioversion therapy that treats atrial arrhythmias within pain tolerance thresholds of a patient. An implantable therapy generator adapted to generate and selectively deliver a three-stage atrial cardioversion therapy and at least two leads operably each having at least one electrode adapted to be positioned proximate the atrium of the patient. The device is programmed with a set of therapy parameters for delivering a three-stage atrial cardioversion therapy to the patient via both a far-field configuration and a near-field configuration of the electrodes upon detection of an atrial arrhythmia. The three-stage atrial cardioversion therapy includes a first stage for unpinning of one or more singularities associated with an atrial arrhythmia, a second stage for anti-repinning of the one or more singularities associated with the atrial arrhythmia, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities associated with the atrial arrhythmia delivered via the near-field configuration of the electrodes. | 01-13-2011 |
Vladimir D. Fedorov, Bellevue, WA US
| Patent application number | Description | Published |
|---|---|---|
| 20090248693 | MANAGING DATA TRANSFER BETWEEN ENDPOINTS IN A DISTRIBUTED COMPUTING ENVIRONMENT - A file fetcher manager provides commonly-utilized management and resource allocation for multiple file fetchers that each implement a different type of mechanism or protocol for transferring data files between peer endpoints in meshes associated with a cloud-computing service. Each file fetcher is configured with both client-side and server-side components to retrieve and serve out data files. The file fetcher manager encapsulates the file fetchers to provide an abstract interface to callers while hiding the underlying details of the file fetchers. The file fetcher manager is arranged for managing simultaneous operations of the multiple file fetchers to route requests from the callers to the appropriate file fetchers, and for scheduling work items for the file fetchers so that data transfers efficiently utilize available resources while keeping the entire transfer process coherent and organized. | 10-01-2009 |
| 20090300169 | SYNCHRONIZATION THROTTLING BASED ON USER ACTIVITY - Synchronization of data across multiple endpoints in a mesh network that supports a data sharing service is throttled responsively to user activity in the network by monitoring the activity using a component in a mesh operating environment (“MOE”) runtime that is instantiated on each endpoint. The monitoring may include the collection of data that can be used to infer user activity, as well as data that explicitly indicates activity. State information is maintained so that data can be synchronized across the endpoints even when a user goes offline from the service. When the user logs on to the service, makes changes to a shared file, or the endpoint device starts up upon connection to a mesh network, throttling is performed by prioritizing work items associated with synchronization operations so that resources on the endpoint are not excessively consumed which could reduce the quality of the user experience. | 12-03-2009 |
Vladimir Dmitri Fedorov, Bellevue, WA US
| Patent application number | Description | Published |
|---|---|---|
| 20080317068 | SERVER-ASSISTED AND PEER-TO-PEER SYNCHRONIZATION - Systems and methods for synchronizing data between endpoints using elements of centralized and decentralized synchronization systems and communication topologies are disclosed. Such systems and methods may in some cases synchronize some subset of data with a centralized endpoint while another subset of data is synchronized in a decentralized fashion directly with other endpoints. Such systems and methods may include a variety of cooperative functionality to assist in the synchronization of data between endpoints. | 12-25-2008 |
| 20090241134 | REMOTE STORAGE SERVICE API - Techniques are disclosed to provide an application programming interface to access data stored in a remote storage service. The data may be of any type, and is stored in core objects. | 09-24-2009 |
Vladimir V. Fedorov, Vestavia Hills, AL US
| Patent application number | Description | Published |
|---|---|---|
| 20090304034 | Electrically Pumped Broadly Tunable Mid-Infrared Lasers based on Quantum Confined Transition Metal Doped Semiconductors - Electrically pumped mid-IR semiconductor lasers that are operable at room temperature and possess a range of tunability up to 1100 nm, which constitutes a revolutionary (1-2 orders of magnitude) improvement in the range of tunability over existing semiconductor laser technology utilizing Doped quantum confined host material (DQCH) with characteristic spatial dimension of the confinement tuned to enable the overlap of the discrete levels of the host and impurity ions and efficient energy transfer from the separated host carriers to the impurity, wherein: said DQCH material has the formula TM:MeZ and/or MeX | 12-10-2009 |
Vladimir V. Fedorov, Birmingham, AL US
| Patent application number | Description | Published |
|---|---|---|
| 20100022049 | Mid-IR Microchip Laser: ZnS:Cr2+ Laser with Saturable Absorber Material - A method of fabrication of laser gain material and utilization of such media includes the steps of introducing a transitional metal, preferably Cr | 01-28-2010 |
| 20100246610 | Mid-IR Laser Instrument for Analyzing a Gaseous Sample and Method for Using the Same - An optical nose for detecting the presence of molecular contaminants in gaseous samples utilizes a tunable seed laser output in conjunction with a pulsed reference laser output to generate a mid-range IR laser output in the 2 to 20 micrometer range for use as a discriminating light source in a photo-acoustic gas analyzer. | 09-30-2010 |
Yuriy Fedorov, Superior, CO US
| Patent application number | Description | Published |
|---|---|---|
| 20090280567 | STABILIZED SIRNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS - RNA molecules, including siRNA molecules and related control, trackability and exaequo agents with specific stability modifications are provided. These molecules are particularly advantageous as transfection control reagents. The molecules include first and second 5′ terminal sense nucleotides with 2′-O-alkyl groups and a label on the first 5′ terminal sense nucleotide, in conjunction with at least one additional 2′-O-alkyl pyrimidine modified sense nucleotide, and either: (i) at least one 2′ fluoro modified pyrimidine antisense nucleotide and a phosphorylated first 5′ terminal antisense nucleotide; or (ii) a first and second 5′ terminal antisense nucleotide with 2′-O-alkyl modifications and at least one additional 2′-O-alkyl pyrimidine modified antisense nucleotide. | 11-12-2009 |
| 20100173359 | ENHANCED BIOTHERAPEUTIC PRODUCTION USING INHIBITORY RNA - Compositions, kits, systems, equipment, and protocols utilize synthetic siRNA having a delivery facilitating moiety in improved bioprocesses that enhance the production of biomaterials. The siRNA can target genes associated with the following: 1) deleterious vector derived genes; 2) genes that confer non-optimal growth or differentiation properties to the cells; 3) genes that can influence heterogeneity or post-translational modification pattern of the desirable gene product; 4) genes that highly express non-desired proteins; 5) genes that express proteins which interfere with purification of the desired protein; and 6) other genes that can interfere with the bioprocess. | 07-08-2010 |
| 20100184209 | COMPOSITIONS AND METHODS FOR INHIBITING GENE SILENCING BY RNA INTERFERENCE - The present invention provides compositions and methods for inhibiting gene silencing by the RNAi pathway. The RNAi inhibitors of the invention have a reverse complement (RC) region to the target molecule of interest (e.g., miRNA) in association with at least one flanking region coupled to either at the 3′ or 5′ end of the RC region. The flanking regions can be single-stranded or can have one or more regions of double stranded nucleic acid with or without a hairpin loop. The RNAi inhibitors described herein can inhibit endogenous targets, including but not limited to microRNAs, or piRNAs, or can be used to inhibit the effects of exogenously introduced molecules, such as synthetic siRNAs, siRNAs expressed from vector constructs (e.g., viral expression systems), or siRNAs generated by enzymatic methods. Inhibition is specific, potent, prolonged, and can be performed on a single target or multiple targets simultaneously. | 07-22-2010 |
| 20100197023 | MODIFIED POLYNUCLEOTIDES FOR USE IN RNA INTERFERENCE - Methods and compositions for performing RNA interference comprising a wide variety of stabilized siRNAs suitable for use in serum-containing media and for in vivo applications, such as therapeutic applications, are provided. These siRNAs permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of one or more modifications including orthoesters, terminal conjugates, modified linkages and 2′ modified nucleotides. Uniquely modified siRNAs have been developed that reduces off-target effects incurred in gene-silencing. The modifications include phosphorylation of the first 5′ terminal antisense nucleotide; 2′ carbon modifications of the first and second or first, second, and third 5′ terminal antisense nucleotides; and optionally 2′ carbon modifications of the first and second or first, second, and third 5′ terminal sense nucleotide. Control and exaequo molecules are also provided. siRNA molecules and related control, trackability and exaequo agents with specific stability modifications were developed. | 08-05-2010 |